Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02318368 |
| Title | A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label |
| Acronym | FOCAL |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | AVEO Pharmaceuticals, Inc, Biodesix |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | ITA | AUS |